NASDAQ:TXMD TherapeuticsMD - TXMD Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding TherapeuticsMD, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $5.20 -0.05 (-0.95%) (As of 02/3/2023 12:00 AM ET) Add Compare Share Share Today's Range$5.15▼$5.4050-Day Range$4.23▼$7.0952-Week Range$1.99▼$23.00Volume34,511 shsAverage Volume54,653 shsMarket Capitalization$48.98 millionP/E RatioN/ADividend YieldN/APrice Target$125.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media TherapeuticsMD MarketRank™ ForecastAnalyst RatingHold2.00 Rating ScoreUpside/Downside2,303.8% Upside$125.00 Price TargetShort InterestHealthy3.82% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingAcquiring Shares$204,124 Bought Last QuarterProj. Earnings GrowthDecreasingFrom $2.47 to ($0.79) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.75 out of 5 starsMedical Sector781st out of 1,028 stocksPharmaceutical Preparations Industry384th out of 501 stocks 3.0 Analyst's Opinion Consensus RatingTherapeuticsMD has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $125.00, TherapeuticsMD has a forecasted upside of 2,303.8% from its current price of $5.20.Amount of Analyst CoverageTherapeuticsMD has only been the subject of 1 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted3.82% of the float of TherapeuticsMD has been sold short.Short Interest Ratio / Days to CoverTherapeuticsMD has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in TherapeuticsMD has recently decreased by 4.06%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldTherapeuticsMD does not currently pay a dividend.Dividend GrowthTherapeuticsMD does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TXMD. Previous Next 1.1 News and Social Media Coverage News SentimentTherapeuticsMD has a news sentiment score of -1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.47 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for TherapeuticsMD this week, compared to 3 articles on an average week.Search InterestOnly 12 people have searched for TXMD on MarketBeat in the last 30 days. This is a decrease of -43% compared to the previous 30 days.MarketBeat Follows9 people have added TherapeuticsMD to their MarketBeat watchlist in the last 30 days. This is an increase of 350% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, TherapeuticsMD insiders have bought 291.71% more of their company's stock than they have sold. Specifically, they have bought $204,124.00 in company stock and sold $52,111.00 in company stock.Percentage Held by InsidersOnly 8.80% of the stock of TherapeuticsMD is held by insiders.Percentage Held by InstitutionsOnly 22.00% of the stock of TherapeuticsMD is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for TherapeuticsMD are expected to decrease in the coming year, from $2.47 to ($0.79) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of TherapeuticsMD is -3.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of TherapeuticsMD is -3.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About TherapeuticsMD (NASDAQ:TXMD) StockTherapeuticsMD, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of products for women. The firm's technology, SYMBODA, develops advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes. It also manufactures and distributes branded and generic prescription prenatal vitamins, as well as over-the-counter vitamins under the BIJUVA, IMVEXXY, vitaMedMD and BocaGreenMD brands. The company was founded by Robert G. Finizio and Brian A. Bernick in 1907 and is headquartered in Boca Raton, FL.Read More Receive TXMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for TherapeuticsMD and its competitors with MarketBeat's FREE daily newsletter. Email Address TXMD Stock News HeadlinesJanuary 5, 2023 | bizjournals.comTheraputicsMD sells products rights for $153 millionJanuary 3, 2023 | finance.yahoo.comTherapeuticsMD Completes Transaction to License Its Products to Mayne PharmaFebruary 5, 2023 | Wall Street Watch Dogs (Ad)A gold storm is coming…“We are in the early stages of a mania – the calm before the storm.”...December 26, 2022 | reuters.comTXMD.A - TherapeuticsMD Inc | Stock Price & Latest News | ReutersDecember 19, 2022 | bizjournals.comTechnology & Innovation Roundup: Company will cut 212 employees after failed buyoutDecember 16, 2022 | marketwatch.comTherapeuticsMD Inc. stock falls Thursday, underperforms marketDecember 15, 2022 | marketwatch.comTherapeuticsMD Inc. stock rises Wednesday, outperforms marketDecember 4, 2022 | finance.yahoo.comTherapeuticsMD Announces Definitive Agreements to License its Products to Mayne PharmaFebruary 5, 2023 | Wall Street Watch Dogs (Ad)“Future Fuel” will unleash $11 trillion wave of wealthThe next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…November 15, 2022 | finance.yahoo.comTherapeuticsMD Announces Third Quarter 2022 Financial ResultsNovember 15, 2022 | finance.yahoo.comTherapeuticsMD (TXMD) Reports Q3 Loss, Lags Revenue EstimatesNovember 13, 2022 | finance.yahoo.comTherapeuticsMD, Inc. (TXMD) Stock Historical Prices & Data - Yahoo FinanceOctober 31, 2022 | finance.yahoo.comTherapeuticsMD Announces Additional $7 Million Private PlacementOctober 3, 2022 | bizjournals.comTherapeuticsMD receives $7M investment after merger plans unravel - South Florida Business Journal - The Business JournalsOctober 3, 2022 | finance.yahoo.comTherapeuticsMD receives $7M investment after merger plans unravelOctober 3, 2022 | seekingalpha.comTherapeuticsMD rannounces $7 million private placement - Seeking AlphaOctober 3, 2022 | businesswire.comTherapeuticsMD Announces $7 Million Private Placement - Business WireOctober 3, 2022 | finance.yahoo.comTherapeuticsMD Announces $7 Million Private PlacementSeptember 30, 2022 | marketwatch.comTherapeuticsMD Inc. stock outperforms market despite losses on the day - MarketWatchSeptember 17, 2022 | thestreet.comTherapeuticsMD (TXMD) Stock Surges on Successful Vaginal Atrophy Drug TrialSeptember 16, 2022 | finance.yahoo.comPrenatal Vitamin Supplements Market to record USD 230.86 Mn growth -- Driven by increasing number of gynecologists recommending prenatal vitamin supplements to expecting mothers - Yahoo FinanceSeptember 12, 2022 | marketwatch.comTherapeuticsMD CEO O'Dowd Steps Down After Less Than a Year - MarketWatchSeptember 12, 2022 | finance.yahoo.comTherapeuticsMD Appoints Dr. Brian Bernick and Mr. Mark Glickman as Interim Co-Chief Executive Officers - Yahoo FinanceSeptember 12, 2022 | businesswire.comTherapeuticsMD Appoints Dr. Brian Bernick and Mr. Mark Glickman as Interim Co-Chief Executive Officers - Business WireSeptember 12, 2022 | finance.yahoo.comTherapeuticsMD Appoints Dr. Brian Bernick and Mr. Mark Glickman as Interim Co-Chief Executive OfficersSeptember 9, 2022 | benzinga.comTherapeuticsMD (NASDAQ:TXMD) – Looking Into TherapeuticsMD's Return On Capital Employed - BenzingaSeptember 5, 2022 | fool.comTherapeuticsMD, Inc. (NASDAQ: TXMD)See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive TXMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for TherapeuticsMD and its competitors with MarketBeat's FREE daily newsletter. Email Address TXMD Company Calendar Last Earnings11/14/2022Today2/04/2023Next Earnings (Estimated)3/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TXMD Previous SymbolNYSEMKT:TXMD CUSIPN/A CIK25743 Webwww.therapeuticsmd.com Phone(561) 961-1900Fax561-431-3389Employees416Year FoundedN/APrice Target and Rating Average Stock Price Forecast$125.00 High Stock Price Forecast$125.00 Low Stock Price Forecast$125.00 Forecasted Upside/Downside+2,303.8%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.43) Trailing P/E RatioN/A Forward P/E Ratio2.11 P/E GrowthN/ANet Income$-172,410,000.00 Net Margins-9.90% Pretax Margin-9.57% Return on EquityN/A Return on Assets-87.08% Debt Debt-to-Equity RatioN/A Current Ratio0.50 Quick Ratio0.46 Sales & Book Value Annual Sales$86.95 million Price / Sales0.56 Cash FlowN/A Price / Cash FlowN/A Book Value($11.05) per share Price / Book-0.47Miscellaneous Outstanding Shares9,420,000Free Float8,596,000Market Cap$48.98 million OptionableOptionable Beta1.22 Key ExecutivesMarlan WalkerChief Executive OfficerHugh O'DowdPresident & DirectorMichael DoneganChief Financial & Accounting OfficerDaniella SilvaChief Compliance OfficerDouglas Mike SteelmanVice President-Market AccessKey CompetitorsLifeVantageNASDAQ:LFVNVistaGen TherapeuticsNASDAQ:VTGNOrgenesisNASDAQ:ORGSASLAN PharmaceuticalsNASDAQ:ASLNMedicenna TherapeuticsNASDAQ:MDNAView All CompetitorsInsiders & InstitutionsSimplex Trading LLCBought 212,600 shares on 2/2/2023Ownership: 0.000%Equitec Proprietary Markets LLCSold 2,500 shares on 1/31/2023Ownership: 0.000%Michael C DoneganSold 1,648 sharesTotal: $8,371.84 ($5.08/share)Michael C DoneganSold 1,302 sharesTotal: $6,952.68 ($5.34/share)Rubric Capital Management LpBought 14,825 shares on 12/9/2022Total: $90,284.25 ($6.09/share)View All Insider TransactionsView All Institutional Transactions TXMD Stock - Frequently Asked Questions Should I buy or sell TherapeuticsMD stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for TherapeuticsMD in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" TXMD shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TXMD, but not buy additional shares or sell existing shares. View TXMD analyst ratings or view top-rated stocks. What is TherapeuticsMD's stock price forecast for 2023? 2 Wall Street analysts have issued twelve-month price objectives for TherapeuticsMD's stock. Their TXMD share price forecasts range from $125.00 to $125.00. On average, they expect the company's share price to reach $125.00 in the next twelve months. This suggests a possible upside of 2,303.8% from the stock's current price. View analysts price targets for TXMD or view top-rated stocks among Wall Street analysts. How have TXMD shares performed in 2023? TherapeuticsMD's stock was trading at $5.59 on January 1st, 2023. Since then, TXMD shares have decreased by 7.0% and is now trading at $5.20. View the best growth stocks for 2023 here. When is TherapeuticsMD's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 9th 2023. View our TXMD earnings forecast. How were TherapeuticsMD's earnings last quarter? TherapeuticsMD, Inc. (NASDAQ:TXMD) issued its earnings results on Monday, November, 14th. The company reported ($3.13) EPS for the quarter, missing analysts' consensus estimates of ($2.04) by $1.09. The business had revenue of $20.92 million for the quarter, compared to analysts' expectations of $30.20 million. When did TherapeuticsMD's stock split? TherapeuticsMD shares reverse split before market open on Monday, May 9th 2022. The 1-50 reverse split was announced on Monday, May 9th 2022. The number of shares owned by shareholders was adjusted after the market closes on Monday, May 9th 2022. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. What other stocks do shareholders of TherapeuticsMD own? Based on aggregate information from My MarketBeat watchlists, some companies that other TherapeuticsMD investors own include OPKO Health (OPK), Verastem (VSTM), Teva Pharmaceutical Industries (TEVA), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Gilead Sciences (GILD), Cleveland-Cliffs (CLF), Novavax (NVAX) and Micron Technology (MU). What is TherapeuticsMD's stock symbol? TherapeuticsMD trades on the NASDAQ under the ticker symbol "TXMD." Who are TherapeuticsMD's major shareholders? TherapeuticsMD's stock is owned by many different retail and institutional investors. Top institutional shareholders include Simplex Trading LLC (0.00%), XR Securities LLC (0.00%), XR Securities LLC (0.00%), Equitec Proprietary Markets LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Brian Bernick, Cooper C Collins, Edward Borkowski, Gail K Naughton, James Darecca, Marlan D Walker, Marlan D Walker, Michael C Donegan, Michael C Donegan, Paul Bisaro, Robert G Finizio, Rubric Capital Management Lp, Tommy G Thompson and Tommy G Thompson. View institutional ownership trends. How do I buy shares of TherapeuticsMD? Shares of TXMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is TherapeuticsMD's stock price today? One share of TXMD stock can currently be purchased for approximately $5.20. How much money does TherapeuticsMD make? TherapeuticsMD (NASDAQ:TXMD) has a market capitalization of $48.98 million and generates $86.95 million in revenue each year. The company earns $-172,410,000.00 in net income (profit) each year or ($1.43) on an earnings per share basis. How many employees does TherapeuticsMD have? The company employs 416 workers across the globe. How can I contact TherapeuticsMD? TherapeuticsMD's mailing address is 951 Yamato Road Suite 220, BOCA RATON FL, 33431. The official website for the company is www.therapeuticsmd.com. The company can be reached via phone at (561) 961-1900, via email at shareholder@broadridge.com, or via fax at 561-431-3389. This page (NASDAQ:TXMD) was last updated on 2/5/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.